All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
CALLIPER
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
REMODEL
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
CIELO
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
CLOCK-MS
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis (CLOCK-MS)
Himalaya
A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension
Intuition
An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging
ASPIRE
Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)
Celgene Vaccine
A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-pegylated Interferon (IFN)-β or No Disease Modifying Therapy
SPHERES
CorEvitas SPHERES (Synergy of Prospective Health and Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
FENHANCE
A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis
MASTER-2
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS
APOLLOE4
The purpose of this study is to determine if the study drug called ALZ-801 is safe, if it is well tolerated, and if it is effective in treating AD. It is a twice a day oral medication that is taken with meals.
Cassava RefocusALZ
The purpose of this study is to learn more about the use of the study drug, simufilam, for the treatment of Alzheimer’s disease. We want to test that it is safe and to find out whether it can slow down the advance of Alzheimer’s disease.
Alector (FTD)
This project is being done to determine if the experimental drug AL001 is effective and safe in treating individuals who have a known progranulin gene mutation that causes FTD, when compared to placebo (a solution that contains no active AL001 drug).
TREAT MS: Traditional versus Early Aggressive Therapy for Multiple Sclerosis (TREATMS) Trial
The purpose of this research is to identify the most appropriate treatment strategy for people with multiple sclerosis (MS), especially shortly after diagnosis when it may be most possible to increase a patient’s chance for preventing longer-term disability.
Structural and Functional Connectivity Changes in the Brain in Response to Diagnostic Nerve Blocks in Stroke Survivors
Identify changes in brain functional connectivity associated with diagnostic nerve blocks (DNB) to relieve spasticity in stroke survivors.